Characterization of a Novel Phage HZJ33 and Its Application in the Treatment of Carbapenem‐Resistant Klebsiella pneumoniae Infection
APMIS · 2025-09 · 133 (9)
DOI: 10.1111/apm.70068 ↗Kurz gefasst
Fachartikel in der Zeitschrift APMIS, online erschienen am 14.09.2025. Verfasst von Ruici Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, China. Hauptthemen laut MEDLINE: Klebsiella Infections, Klebsiella pneumoniae, Bacteriophages, Phage Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation, Henan Provincial Science and Technology Research Project, Natural Science Foundation of Henan Province.
Abstract (Originalsprache)
Carbapenem‐resistant Klebsiella pneumoniae (CRKP) represents a critical global public health challenge. Phages are regarded as promising alternatives to antibiotics. In this study, a novel lytic phage, HZJ33, was isolated from the clinical CRKP strain KP703. Transmission electron microscopy (TEM) revealed that HZJ33 possessed an icosahedral head and podovirus morphotype. HZJ33 achieved optimal infectivity at a multiplicity of infection (MOI) of 0.01, with a latent period of 10 min and a burst size of 4.65 × 10 4 PFU/cell. It lysed 40% of tested clinical CRKP isolates (12/30). The endotoxin level released from bacterial lysis mediated by phage HZJ33 was well below the established safety threshold and exhibited no detectable cytotoxicity. Whole‐genome analysis confirmed the absence of virulence and antibiotic resistance genes. In vitro, HZJ33 suppressed KP703 growth curves within 10 h. In the Galleria mellonella infection model, HZJ33 treatment at an MOI of 100 increased the larval survival rate to 75%, compared to 25% in the infected negative control group (1 × 10 7 CFU/mL). These findings identify HZJ33 as a lytic phage with a broad host range, high stability, favorable safety, and strong antibacterial activity in vitro and in vivo, supporting its potential for CRKP therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, China.
- The Second Affiliated Hospital of Henan University of Chinese Medicine, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, China.
- The Key Laboratory of Pathogenic Microbes & Antimicrobial Resistance Surveillance of Zhengzhou, China.
- Henan Engineering Research Center for Identification of Pathogenic Microbes, Zhengzhou, China.
- Henan Provincial Key Laboratory of Antibiotics-Resistant Bacterial Infection Prevention & Therapy With Traditional Chinese Medicine, China.
ORCID-Profile: Ruici Lu
Förderung
- Wu Jieping Medical Foundation
- Henan Provincial Science and Technology Research Project
- Natural Science Foundation of Henan Province
- Key Scientific Research project of Henan Higher Education Institutions
Zitieren
APA
Lu, R., Wang, R., Ren, X., Liu, X., You, X., Wang, C., Zhu, R., & Li, Y. (2025). Characterization of a Novel Phage HZJ33 and Its Application in the Treatment of Carbapenem‐Resistant Klebsiella pneumoniae Infection. APMIS, 133(9). https://doi.org/10.1111/apm.70068
Vancouver
Lu R, Wang R, Ren X, Liu X, You X, Wang C, et al. Characterization of a Novel Phage HZJ33 and Its Application in the Treatment of Carbapenem‐Resistant Klebsiella pneumoniae Infection. APMIS. 2025;133(9). doi:10.1111/apm.70068
BibTeX
@article{Lu2025,
author = {Lu, Ruici and Wang, Ruilin and Ren, Xuefang and Liu, Xinwei and You, Xiaojuan and Wang, Chunxia and Zhu, Rui and Li, Yongwei},
title = {Characterization of a Novel Phage HZJ33 and Its Application in the Treatment of Carbapenem‐Resistant Klebsiella pneumoniae Infection},
journal = {APMIS},
year = {2025},
volume = {133},
number = {9},
doi = {10.1111/apm.70068}
}
EUVIMED